

Table VI. Baseline clinical characteristics of patients from the validation set in the AKI-v (n=8) and control-v (n=8) groups.

Item	AKI-v group	Control-v group	P-value
Male sex	5 (62.5)	6 (75.0)	0.590
Age, years	75.50±9.63	74.00±4.95	0.701
BMI, kg/m ²	22.82±2.92	22.19±3.97	0.723
Smoking	1 (12.5)	1 (12.5)	1.000
Hypertension	5 (62.5)	6 (75.0)	0.590
Diabetes mellitus	3 (37.5)	2 (25.0)	0.590
CKD	3 (37.5)	2 (25.0)	0.590
Hemoglobin, g/l	114.38±10.45	112.50±14.68	0.773
Albumin, g/l	35.58±4.44	37.65±4.24	0.359
Baseline eGFR, ml/min/1.73 m ²	73.59±26.44	66.88±17.97	0.562
Scr, μmol/l			
Baseline	87.90±32.15	94.27±29.02	0.684
Post-24 h	101.77±43.62	90.50±27.39	0.546
Post-48 h	124.86±42.88	92.41±22.44	0.079
BNP, pg/ml	4084 (379,6258)	655 (345,1628)	0.279
LVEF (%)	61.13±8.74	60.13±9.28	0.828
TC, mmol/l	3.94±0.81	3.49±0.75	0.272
TG, mmol/l	1.52±0.53	1.16±0.27	0.388
HDL-C, mmol/l	0.98±0.32	1.26±0.42	0.153
LDL-C, mmol/l	2.26±0.81	1.69±0.51	0.121
ApoA-I, g/l	1.07±0.20	1.27±0.22	0.099
ApoB, g/l	0.80±0.28	0.63±0.13	0.167
ApoE, mg/dl	3.88±1.71	4.37±0.99	0.253
Lipoprotein (a), mg/l	217.40±197.99	197.38±179.68	0.840
Medication			
Aspirin	8 (100)	8 (100)	1.000
ACEI/ARB	4 (50.0)	4 (50.0)	1.000
CCB	3 (37.5)	2 (25.0)	0.590
β-blocker	7 (82.5)	7 (82.5)	1.000
Diuretics	5 (62.5)	6 (75.0)	0.590
Statins	8 (100)	8 (100)	1.000
Atorvastatin	20.00±0.00	23.33±8.16	0.389
Rosuvastatin	13.33±5.77	15.00±7.07	0.789
Number of diseased vessels	2.38±0.74	2.13±0.99	0.577
Contrast volume, ml	197.50±31.05	181.25±38.71	0.370

Values are expressed as n (%), mean ± standard deviation or the median (25,75th percentile). AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; TC, total cholesterol; TG, total triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; apoA-I, apolipoprotein A-I; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.